Administration of antibody to the lung protects mice against pneumonic plague.
Intratracheal delivery of aerosolized monoclonal antibodies with specificity for Yersinia pestis LcrV and F1 antigens protected mice in a model of pneumonic plague. These data support the utility of inhaled antibodies as a fast-acting postexposure treatment for plague.
Hill
Jim
J
Defence Science and Technology Laboratory, Porton Down, Wiltshire SP4 OJQ, United Kingdom. jhill@dstl.gov.uk
Eyles
Jim E
JE
Elvin
Stephen J
SJ
Healey
Gareth D
GD
Lukaszewski
Roman A
RA
Titball
Richard W
RW
D000336:Aerosols; D000818:Animals; D000907:Antibodies, Bacterial / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D000942:Antigens, Bacterial / Q000276:immunology*; D001426:Bacterial Proteins / Q000276:immunology*; D005260:Female; D051379:Mice; D008807:Mice, Inbred BALB C; D010930:Plague / Q000517:prevention & control*; D052899:Pore Forming Cytotoxic Proteins; D015010:Yersinia pestis / Q000276:immunology*
D000336:Aerosols; D000907:Antibodies, Bacterial; D000911:Antibodies, Monoclonal; D000942:Antigens, Bacterial; D001426:Bacterial Proteins; C043908:LcrV protein, Yersinia; D052899:Pore Forming Cytotoxic Proteins; C086725:caf1 protein, Yersinia pestis